Ocular side effects of biological agents in oncology: What should the clinician be aware of?

OncoTargets and Therapy

Volumn 7, Issue , 2013, Pages 69-77

  Hager, Tobias ^a   Seitz, B ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Biological; Egfr; Interferon; Ocular side effect; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2 ANTIBODY; GEFITINIB; IMATINIB; INTERFERON; IPILIMUMAB; SUNITINIB; TAMOXIFEN; UNCLASSIFIED DRUG; VANDETANIB;

ACCOMMODATION DISORDER; ARTICLE; AWARENESS; BLEPHARITIS; BLURRED VISION; CANCER THERAPY; CENTRAL SCOTOMA; CEREBRAL BLINDNESS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA EROSION; CORNEA VERTICILLATA; CRYSTALLINE RETINOPATHY; DIPLOPIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DRY EYE; EXOPHTHALMOS; EYE DISEASE; HEADACHE; HUMAN; IRIDOCYCLITIS; ISCHEMIC OPTIC NEUROPATHY; KERATITIS; KERATOPATHY; MYASTHENIA GRAVIS; MYDRIASIS; NERVE PARALYSIS; NEUROLOGIC DISEASE; ONCOLOGIST; OPHTHALMOLOGIST; OPTIC NEURITIS; ORBITAL MYOSITIS; PAPILLEDEMA; PAPILLITIS; PERIORBITAL EDEMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINA VEIN OCCLUSION; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; TONIC CLONIC SEIZURE; TRICHIASIS; UNSPECIFIED SIDE EFFECT; VASOSPASM; VISUAL DISORDER; VISUAL IMPAIRMENT; VITREOUS FLOATERS;

EID: 84891461956     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S54606     Document Type: Article

References (82)

1. Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol. 2012.
2. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30(26):3277-3286.
3. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309-335.
4. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004;79(5):677-688.
5. Chalam KV, editor. Basic and Clinical Science Course: Fundamentals and Principles of Ophthalmology. 1st ed. San Francisco: American Academy of Ophthalmology; 2011.
6. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Cancer Institute; 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 11, 2013.
7. Pfizer Labs. Food and Drug Administration: Highlights of Prescribing Information XALKORI. New York: Pfizer Labs; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf. Accessed October 11, 2013.
8. Agustoni F, Platania M, Vitali M, et al. Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. Cancer Treat Rev. 2013.
9. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10): 1011-1019.
10. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19(4):371-375.
11. Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases. Dermatitis. 2012;23(5): 237-238.
12. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798-1802.
13. Xu KP, Ding Y, Ling J, Dong Z, Yu FS. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(3):813-820.
14. Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862-873.
15. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001;72(5):511-517.
16. Liu S, Kam WR, Ding J, Hatton MP, Sullivan DA. Effect of growth factors on the proliferation and gene expression of human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci. 2013;54(4): 2541-2550.
17. Fraunfelder FT, Fraunfelder FW. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol. 2012;31(3):195-197.
18. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J. 2009;15(3):4.
19. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005;19(7): 729-738.
20. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4): 1167-1174.
21. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1): 77-85.
22. Garibaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg. 2007;23(1):62-63.
23. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798-1802.
24. Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008;27(5):612-614.
25. Ibrahim E, Dean WH, Price N, et al. Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report. Case Rep Ophthalmol Med. 2012;2012:379132.
26. Dib E, Maia M, Lima Ade S, et al. In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate. Curr Eye Res. 2012;37(7): 567-574.
27. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18(10): 1745-1747.
28. Chelis L, Souftas V, Amarantidis K, et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer. 2012;12:489.
29. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77(1):72-76.
30. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475-1478.
31. Hadj JO, Braven RD, Tillier C, Schrijver HM, Verheul HM, VAN DER Vliet HJ. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncol Lett. 2012;3(6):1293-1296.
32. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980-982; discussion 980-982.
33. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004-1012.
34. Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008;32(7): 1022-1025.
35. Shome D, Trent J, Espandar L, et al. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology. 2008;115(3):483-487.
36. DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci. 2012;89(10):e16-e22.
37. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008;52(4): 331-333.
38. Govind Babu K, Attili VS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007;27(1):43-44.
39. McClelland CM, Harocopos GJ, Custer PL. Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol. 2010;4:427-431.
40. Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea. 2009;28(6):699-702.
41. Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol. 2011;25(5):355-357.
42. Schlote T, Freudenthaler SM, Stübiger N, Zierhut M. Medikamentöse Nebenwirkungen am Auge. 1. Auflage, Stuttgart: Thieme, 2001.
43. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010; 13(1):29-38.
44. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593-598.
45. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164(2): 303-307.
46. Borodic GE, Hinkle DM. Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression". Ophthal Plast Reconstr Surg. 2003;29(3):241.
47. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681-6688.
48. Lecouflet M, Verschoore M, Giard C, et al. [Orbital myositis associated with ipilimumab]. Ann Dermatol Venereol. 2013;140(6-7):448-451.French.
49. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36(4): 518-520.
50. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27(6):478-479.
51. Kalli F, Machiorlatti R, Battaglia F, et al. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. J Transl Med. 2013;11:120.
52. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol. 2013;32(4):341-343.
53. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49(1): 25-37.
54. Castel V, Segura V, Cañete A. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin Transl Oncol. 2010;12(12):788-793.
55. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.
56. Kremens B, Hero B, Esser J, et al. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol Immunother. 2002;51(2):107-110.
57. Gianni L, Panzini I, Li S, et al; International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006;106(3):505-513.
58. Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond). 1999;13(Pt 6):729-733.
59. Ritter C, Renner AB, Wachtlin J, Bechrakis NE, Krause L. [Tamoxifen retinopathy: a case series of clinical and functional data]. Ophthalmologe. 2008;105(6):544-549. German.
60. Hager T, Hoffmann S, Seitz B. [Unusual symptoms for tamoxifen-associated maculopathy]. Ophthalmologe. 2010;107(8):750-752. German.
61. Eisner A, Thielman EJ, Falardeau J, Vetto JT. Vitreo-retinal traction and anastrozole use. Breast Cancer Res Treat. 2009;117(1):9-16.
62. Yanyali AC, Freund KB, Sorenson JA, Slakter JS, Wheatley HM. Tamoxifen retinopathy in a male patient. Am J Ophthalmol. 2001; 131(3):386-387.
63. Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005; 26(3):101-105.
64. Flaxel CJ, Mulholland B, Haynes B, Gregor ZJ. Intraocular penetration of tamoxifen. Ophthalmology. 2000;107(11):2006-2009.
65. Mannerström M, Zorn-Kruppa M, Diehl H, et al. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol In Vitro. 2002;16(2):193-200.
66. Mannerström M, Mäenpää H, Toimela T, Salminen L, Tähti H. The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures. Pharmacol Toxicol. 2001;88(1): 27-33.
67. Cho KS, Yoon YH, Choi JA, Lee SJ, Koh JY. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Vis Sci. 2012;53(9):5344-5353.
68. Eisner A, Toomey MD, Falardeau J, Samples JR, Vetto JT. Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat. 2007;106(2):161-170.
69. Colley SM, Elston JS. Tamoxifen optic neuropathy. Clin Experiment Ophthalmol. 2004;32(1):105-106.
70. Kadayifcilar S, Boyacioglu S, Kart H, Gursoy M, Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond). 1999;13(Pt 2):241-246.
71. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol. 2004;88(12): 1518-1520.
72. Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30(6):597-602.
73. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111(3):350-356.
74. Schapira D, Nahir AM, Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum. 2002;32(3):157-162.
75. Jenisch T, Dietrich-Ntoukas T, Renner AB, Helbig H, Gamulescu MA. [Combined retinal artery and vein occlusions associated with interferon beta therapy]. Ophthalmologe. 2012;109(1):71-75. German.
76. Rubio JE, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina. 2003;23(4):546-548.
77. Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology. 2011;118(2):408-411.e1.
78. Kirchhoff A, Kirchhoff U, Lafrenz M, Guthoff R. [Bilateral AION after the combined therapy of hepatitis C with PEG-interferon alpha2B and ribavirin]. Klin Monbl Augenheilkd. 2004;221(9):791-793.German.
79. Wei YH, Wang IH, Woung LC, Jou JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm. 2009;17(3):191-194.
80. Oishi A, Miyamoto K, Kashii S, Yoshimura N. Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol. 2005;89(11):1542-1543.
81. Oishi A, Miyamoto K, Kashii S, Yoshimura N. Abducens palsy and Sjogren's syndrome induced by pegylated interferon therapy. Br J Ophthalmol. 2007;91(6):843-844.
82. Hammam T, McFadzean RM, Ironside JW. Anti-hu paraneoplastic syndrome presenting as bilateral sixth cranial nerve palsies. J Neuroophthalmol. 2005;25(2):101-104.